|
Age, mean ± SD, years*
|
40.1 ±18.6
|
26.1 ± 8.0
|
0.006
|
|
Male/Female distribution, N (%) ▲
|
20/25(55%/45%)
|
20/20(50%/50%)
|
0.653
|
|
Prodromal symptoms, N (%) ▲
| | | |
|
Fever(T > 38.5)
|
28(78)
|
16(40)
|
0.001
|
|
Cough
|
26(72)
|
28(70)
|
1.000
|
|
Dyspnea
|
13(36)
|
0
|
<0.001
|
|
Gastrointestinal
|
4(11)
|
3(7)
|
0.702
|
|
Myalgia
|
23(64)
|
10(25)
|
0.001
|
|
Co-morbidities, N (%) ▲
| | | |
|
COPD
|
12(33)
|
0
|
<0.001
|
|
Coronary artery disease
|
4(11)
|
0
|
<0.001
|
|
Diabetes mellitus
|
5(14)
|
2(5)
|
0.246
|
|
Hypertension
|
5(14)
|
2(5)
|
0.246
|
|
Pregnancy
|
4(11)
|
1(2.5)
|
0.131
|
|
Others (Hypothyroidism, Immunosuppression, Transplant)
|
3(8)
|
0
|
0.102
|
|
Changes in lung imaging examination, N (%) ▲
|
20(55)
|
3(7)
|
<0.001
|
|
Patients using Oseltamivir, N (%) ▲
|
36(100)
|
40(100)
|
1.000
|
|
Oseltamivir treatment time, mean ± SD, (days)*
|
8.55 ± 3.39
|
3.60 ± 1.00
|
<0.001
|
|
Patients using combined glucocorticoid, N (%) ▲
|
19(53)
|
0
|
<0.001
|
|
The number of people using the ventilato, N (%) ▲
|
5(14)
|
0
|
<0.001
|
|
Average stay, mean ± SD, days*
|
13.71 ± 4.77
|
3.37 ± 1.06
|
<0.001
|
|
Death toll, N (%) ▲
|
1(3)
|
0
|
0.474
|
